Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

OBJECTIVE: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon...

Descripción completa

Detalles Bibliográficos
Autores principales: Knerr, Patrick J., Mowery, Stephanie A., Douros, Jonathan D., Premdjee, Bhavesh, Hjøllund, Karina Rahr, He, Yantao, Kruse Hansen, Ann Maria, Olsen, Anette K., Perez-Tilve, Diego, DiMarchi, Richard D., Finan, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305623/
https://www.ncbi.nlm.nih.gov/pubmed/35809773
http://dx.doi.org/10.1016/j.molmet.2022.101533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305623/
https://www.ncbi.nlm.nih.gov/pubmed/35809773
http://dx.doi.org/10.1016/j.molmet.2022.101533

Ejemplares similares